Raise closed, search for fresh raises on Seedstage

Reno, NV

Advancing a patented collagen-based gel for rapid tissue regeneration in wound care, aesthetics, and dental applications.

• Innovative biomaterial gel: Patented collagen-based formula designed to stimulate natural tissue regeneration.
• Multi-market potential: Applications span wound care, aesthetics, and dental industries.
• Regulatory pathway: Preparing for 510(k) submission to accelerate FDA clearance.
• Experienced leadership: Team includes medical and regulatory experts with decades of industry success.
• Long-term advantage: Protected by international patents with an estimated multi-year lead over competitors.

Conexeu is raising funds to advance the development and regulatory approval of its patented collagen-based biomaterial gel, designed to accelerate natural tissue regeneration. Developed over 12 years and protected by international patents, this gel aims to help wounds begin healing within minutes, potentially reducing recovery times significantly compared to current market leaders. The company’s first target is the advanced wound care market, where the product could provide a natural, non-toxic alternative to skin grafts and synthetic materials, offering a faster and less inflammatory option for hospitals, clinics, and trauma care.

Beyond wound care, Conexeu plans to expand into the multi-billion-dollar aesthetics market, positioning its technology as a new category of regenerative treatment for anti-aging and cosmetic enhancement. By stimulating the body’s own collagen production, the gel may offer longer-lasting and more natural results compared to existing dermal fillers. Additional potential applications include dental procedures, where the gel could replace traditional scaffolds with a customizable, injectable solution that promotes tissue regeneration in hard-to-access areas. Funds from this raise will support the push through FDA 510(k) clearance and continued product development, aiming to establish Conexeu as a key innovator across multiple high-growth healthcare markets.

Company Info

Conexeu Sciences develops patented collagen-based biomaterials designed to accelerate natural tissue regeneration for wound care, aesthetics, and dental applications.

Conexeu Sciences is a biotechnology company developing a patented collagen-based biomaterial gel intended to accelerate human tissue regeneration. Its core product, branded as 10 Minute Tissue, is designed to work with the body’s natural processes by creating a biocompatible environment that encourages tissue to regrow, potentially beginning within minutes of application. The company’s initial focus is on the advanced wound care market, which includes treatments for chronic wounds, burns, and traumatic injuries, where current solutions often involve grafts, fillers, or scaffolds that may cause inflammation or use foreign substances. Conexeu’s gel aims to provide a non-toxic, non-inflammatory alternative that uses collagen, the body’s most abundant protein, to promote natural healing at the cellular level.

Beyond wound care, Conexeu plans to expand into the medical aesthetics sector, positioning its product as a potential replacement for traditional dermal fillers by regenerating tissue rather than simply adding volume. The company also sees potential applications in dental biomaterials, offering a less invasive method for procedures like implants and bone grafts. With international patents and a team experienced in FDA clearances, Conexeu is targeting multiple billion-dollar markets and pursuing regulatory approval to bring its technology into hospitals, clinics, and aesthetic practices worldwide.